From correspondents in Tamilnadu, India, 08:32 PM IST
TotipotentSC Scientific Product (Private) Limited, a subsidiary of US based TotipotentSC, an MK Alliance Inc. company, today opened a new headquarters for South East Asia in Chennai, India. Toti is focused on marketing and manufacturing a complete range of stem cell biology and immunology products to scientists and clinicians . The company also offers consulting in Good Manufacturing Practices and Good Tissue Practices for public and private institutions planning to move from benchtop to bedside.
The highly specialized cell biology reagents and equipment product line will be the largest stem cell portfolio in India, and will also include such well respected suppliers as BioLegend (USA), Apollo Cytokine Research (Australia), Cell Sciences (USA), American Fluoroseal Corporation (USA), CellGenix (Germany), and BioSpherix (USA). Additionally, TotipotentSC will have the most significant product range for use in clinical cell processing which will meet Good Manufacturing Practices (GMP) standards.
“We are excited to launch our company in India, which is quickly emerging as one of the most important stem cell markets globally. Coming to Asia, and more specifically India, is a strategic decision, and we are extremely proud to contribute our part to this wonderful region rich in science and culture”, says Ken Harris, Chairman.
The stem cell market in India represents approximately 15-20% of the world’s clinical trials, and government and private investing is growing at a strong double digit annual rate.
“We are excited to launch our company to meet the growing needs of cell biology, cancer biology, immunology and stem cell biology customers in India and South East Asia. We will collaborate with customers as a strategic partner to tackle their most complex issues from basic research to translational research to clinical for human health problems” says Srikumar Kasthuri, Executive Director.
Most Recent Comments
View all comments »